{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:38:33Z","timestamp":1791315513741,"version":"4.3.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272913"],"award-info":[{"award-number":["82272913"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341002 & 32293192 & 82030083"],"award-info":[{"award-number":["82341002 & 32293192 & 82030083"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-2019AZZD-0355"],"award-info":[{"award-number":["Y-2019AZZD-0355"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-QL2019-0125"],"award-info":[{"award-number":["Y-QL2019-0125"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["YG2021QN121"],"award-info":[{"award-number":["YG2021QN121"]}],"id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Oncogenic KRAS mutations are frequently detected in NSCLC. It remains a major challenge to target all KRAS mutants. MEK inhibitors are considered candidates for treating KRAS-mutant NSCLC; however, their easy adaptive resistance precludes further application. Here, we found that MEK inhibitor-trametinib treatment results in the feedback activation of multiple receptor tyrosine kinases (RTKs) and that treatment with the pan-RTK inhibitor anlotinib effectively inhibits the progression of KRAS-mutant NSCLC. Furthermore, we evaluated this strategy in a clinical study (NCT04967079) involving 33 advanced non-G12C KRAS-mutant NSCLC patients. The phase Ia containing 13 patients showed that the recommended phase 2 dose (RP2D) is trametinib (2\u2009mg) plus anlotinib (8\u2009mg), the objective response rate (ORR) is 69.2% (95% CI: 38.6-90.9), the median progression-free survival (PFS) is 6.9 months (95% CI: 3.9 to could not be evaluated), disease control rate (DCR) is 92% (95% CI: 64.0\u201399.8) and the rate of adverse events (AEs) \u2265grade 3 is 23%. The phase Ib containing 20 patients demonstrated the high efficacy of this combinational therapy with RP2D, with the ORR at 65% (95% CI: 40.8\u201384.6), the median PFS is 11.5 months (95% CI: 8.3\u201315.5), the median overall survival (OS) is 15.5 months (95% CI: 15.5 to could not be evaluated), the DCR at 100% (95% CI: 83.2\u2013100.0), the median duration of overall response (DoR) is 9.3 months (95% CI: 2.5\u201312.1), and the rate of AEs \u2265 grade 3 at 35%. Overall, this study provides a potential combinational therapeutic strategy for KRAS-mutant NSCLC through the cotargeting of MEK and RTKs.<\/jats:p>","DOI":"10.1038\/s41392-025-02382-w","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T23:02:35Z","timestamp":1757631755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Coinhibition of the MEK\/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Jun","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqing","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4295-6371","authenticated-orcid":false,"given":"Xinlei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0984-9807","authenticated-orcid":false,"given":"Liang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiqin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runbo","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7909-8757","authenticated-orcid":false,"given":"Yingli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-6390","authenticated-orcid":false,"given":"Hongbin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"2382_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"2382_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen, P., Liu, Y., Wen, Y. & Zhou, C. Non-small cell lung cancer in China. Cancer Commun. 42, 937\u2013970 (2022).","journal-title":"Cancer Commun."},{"key":"2382_CR3","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti, A. K., Klein, A. B., Cotarla, I., Seal, B. & Chou, E. Update of incidence, prevalence, survival, and initial treatment in patients with non\u2013small cell lung cancer in the US. JAMA Oncol. 7, 1824\u20131832 (2021).","journal-title":"JAMA Oncol."},{"key":"2382_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 599, 679\u2013683 (2021).","journal-title":"Nature"},{"key":"2382_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","volume":"37","author":"M Drosten","year":"2020","unstructured":"Drosten, M. & Barbacid, M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell 37, 543\u2013550 (2020).","journal-title":"Cancer Cell"},{"key":"2382_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cancergen.2016.03.001","volume":"209","author":"A Biernacka","year":"2016","unstructured":"Biernacka, A. et al. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genet 209, 195\u2013198 (2016).","journal-title":"Cancer Genet"},{"key":"2382_CR7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","volume":"39","author":"J Timar","year":"2020","unstructured":"Timar, J. & Kashofer, K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 39, 1029\u20131038 (2020).","journal-title":"Cancer Metastasis Rev."},{"key":"2382_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","volume":"19","author":"AR Moore","year":"2020","unstructured":"Moore, A. R., Rosenberg, S. C., McCormick, F. & Malek, S. RAS-targeted therapies: is the undruggable drugged?. Nat. Rev. Drug Discov. 19, 533\u2013552 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2382_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target. Ther. 6, 386 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2382_CR10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/CM9.0000000000003405","volume":"138","author":"J Lu","year":"2025","unstructured":"Lu, J. et al. The role of silent mutations in KRAS-mutant tumors. Chin. Med. J. 138, 278\u2013288 (2025).","journal-title":"Chin. Med. J."},{"key":"2382_CR11","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p. G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2382_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne, P. A. et al. Adagrasib in non\u2013small-cell lung cancer harboring a KRASG12C mutation. N. Engl. J. Med. 387, 120\u2013131 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2382_CR13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2303810","volume":"389","author":"A Sacher","year":"2023","unstructured":"Sacher, A. et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N. Engl. J. Med. 389, 710\u2013721 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2382_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.tranon.2019.12.004","volume":"13","author":"L Lei","year":"2020","unstructured":"Lei, L. et al. A real-world study in advanced non\u2013small cell lung cancer with KRAS mutations. Transl. Oncol. 13, 329\u2013335 (2020).","journal-title":"Transl. Oncol."},{"key":"2382_CR15","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","volume":"13","author":"JC Hunter","year":"2015","unstructured":"Hunter, J. C. et al. Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol. Cancer Res. 13, 1325\u20131335 (2015).","journal-title":"Mol. Cancer Res."},{"key":"2382_CR16","doi-asserted-by":"crossref","unstructured":"Pandey, D., Chauhan, S. C., Kashyap, V. & Roy, K. K. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers. Eur. J. Med. Chem. 116771 (2024).","DOI":"10.1016\/j.ejmech.2024.116771"},{"key":"2382_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","volume":"14","author":"PA J\u00e4nne","year":"2013","unstructured":"J\u00e4nne, P. A. et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 14, 38\u201347 (2013).","journal-title":"Lancet Oncol."},{"key":"2382_CR18","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2017.3438","volume":"317","author":"PA J\u00e4nne","year":"2017","unstructured":"J\u00e4nne, P. A. et al. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non\u2013small cell lung cancer: the SELECT-1 randomized clinical trial. JAMA 317, 1844\u20131853 (2017).","journal-title":"JAMA"},{"key":"2382_CR19","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/annonc\/mdv072","volume":"26","author":"G Blumenschein Jr","year":"2015","unstructured":"Blumenschein, G. Jr et al. A randomized phase II study of the MEK1\/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 26, 894\u2013901 (2015).","journal-title":"Ann. Oncol."},{"key":"2382_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-020-2760-4","volume":"588","author":"ZM Khan","year":"2020","unstructured":"Khan, Z. M. et al. Structural basis for the action of the drug trametinib at KSR-bound MEK. Nature 588, 509\u2013514 (2020).","journal-title":"Nature"},{"key":"2382_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nature18600","volume":"534","author":"E Manchado","year":"2016","unstructured":"Manchado, E. et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 534, 647\u2013651 (2016).","journal-title":"Nature"},{"key":"2382_CR22","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","volume":"8","author":"C Fedele","year":"2018","unstructured":"Fedele, C. et al. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in multiple cancer models. Cancer Discov. 8, 1237\u20131249 (2018).","journal-title":"Cancer Discov."},{"key":"2382_CR23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","volume":"25","author":"P Lito","year":"2014","unstructured":"Lito, P. et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 25, 697\u2013710 (2014).","journal-title":"Cancer Cell"},{"key":"2382_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","volume":"149","author":"JS Duncan","year":"2012","unstructured":"Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307\u2013321 (2012).","journal-title":"Cell"},{"key":"2382_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2159-8290.CD-16-0653","volume":"7","author":"JS Zawistowski","year":"2017","unstructured":"Zawistowski, J. S. et al. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb Complex. Cancer Discov. 7, 302\u2013321 (2017).","journal-title":"Cancer Discov."},{"key":"2382_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-01025-7","volume":"14","author":"J Han","year":"2021","unstructured":"Han, J. et al. MEK inhibitors for the treatment of non-small cell lung cancer. J. Hematol. Oncol. 14, 1\u201312 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2382_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","volume":"4","author":"J Luo","year":"2003","unstructured":"Luo, J., Manning, B. D. & Cantley, L. C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4, 257\u2013262 (2003).","journal-title":"Cancer Cell"},{"key":"2382_CR28","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1038\/sj.onc.1210394","volume":"26","author":"M McKay","year":"2007","unstructured":"McKay, M. & Morrison, D. Integrating signals from RTKs to ERK\/MAPK. Oncogene 26, 3113\u20133121 (2007).","journal-title":"Oncogene"},{"key":"2382_CR29","doi-asserted-by":"publisher","first-page":"1801562","DOI":"10.1183\/13993003.01562-2018","volume":"53","author":"J Lu","year":"2019","unstructured":"Lu, J. et al. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. Eur. Respir. J. 53, 1801562 (2019).","journal-title":"Eur. Respir. J."},{"key":"2382_CR30","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/bjc.2017.478","volume":"118","author":"B Han","year":"2018","unstructured":"Han, B. et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br. J. Cancer 118, 654\u2013661 (2018).","journal-title":"Br. J. Cancer"},{"key":"2382_CR31","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han, B. et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 4, 1569\u20131575 (2018).","journal-title":"JAMA Oncol."},{"key":"2382_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","volume":"654","author":"B Lin","year":"2018","unstructured":"Lin, B. et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1. Gene 654, 77\u201386 (2018).","journal-title":"Gene"},{"key":"2382_CR33","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen, G. et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J. Hematol. Oncol. 11, 120 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2382_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2018.06.008","volume":"432","author":"X Yao","year":"2018","unstructured":"Yao, X. et al. IGFBP2 promotes salivary adenoid cystic carcinoma metastasis by activating the NF-\u03baB\/ZEB1 signaling pathway. Cancer Lett. 432, 38\u201346 (2018).","journal-title":"Cancer Lett."},{"key":"2382_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cytogfr.2014.12.001","volume":"26","author":"V Russo","year":"2015","unstructured":"Russo, V., Azar, W., Yau, S., Sabin, M. & Werther, G. IGFBP-2: The dark horse in metabolism and cancer. Cytokine Growth Factor Rev. 26, 329\u2013346 (2015).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2382_CR36","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1038\/s41388-020-1154-2","volume":"39","author":"T Li","year":"2020","unstructured":"Li, T. et al. IGFBP2: integrative hub of developmental and oncogenic signaling network. Oncogene 39, 2243\u20132257 (2020).","journal-title":"Oncogene"},{"key":"2382_CR37","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim, D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 619, 160\u2013166 (2023).","journal-title":"Nature"},{"key":"2382_CR38","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","volume":"629","author":"M Holderfield","year":"2024","unstructured":"Holderfield, M. et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature 629, 919\u2013926 (2024).","journal-title":"Nature"},{"key":"2382_CR39","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang, J. et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 14, 994\u20131017 (2024).","journal-title":"Cancer Discov."},{"key":"2382_CR40","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/s41416-018-0322-4","volume":"119","author":"AM Schram","year":"2018","unstructured":"Schram, A. M. et al. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K\/MTOR inhibitor voxtalisib in patients with advanced solid tumours. Br. J. Cancer 119, 1471\u20131476 (2018).","journal-title":"Br. J. Cancer"},{"key":"2382_CR41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/1541-7786.MCR-20-0687","volume":"19","author":"R Barbosa","year":"2021","unstructured":"Barbosa, R., Acevedo, L. A. & Marmorstein, R. The MEK\/ERK Network as a Therapeutic Target in Human Cancer. Mol. Cancer Res. 19, 361\u2013374 (2021).","journal-title":"Mol. Cancer Res."},{"key":"2382_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc4000","volume":"15","author":"CJ Caunt","year":"2015","unstructured":"Caunt, C. J., Sale, M. J., Smith, P. D. & Cook, S. J. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat. Rev. Cancer 15, 577\u2013592 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"2382_CR43","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cas.13536","volume":"109","author":"C Xie","year":"2018","unstructured":"Xie, C. et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 109, 1207\u20131219 (2018).","journal-title":"Cancer Sci."},{"key":"2382_CR44","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/ijc.32180","volume":"145","author":"G Wang","year":"2019","unstructured":"Wang, G. et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int. J. Cancer 145, 979\u2013993 (2019).","journal-title":"Int. J. Cancer"},{"key":"2382_CR45","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","volume":"78","author":"YY Syed","year":"2018","unstructured":"Syed, Y. Y. Anlotinib: First Global Approval. Drugs 78, 1057\u20131062 (2018).","journal-title":"Drugs"},{"key":"2382_CR46","doi-asserted-by":"crossref","unstructured":"Oya, Y., Imaizumi, K. & Mitsudomi, T. The next-generation KRAS inhibitors\u2026 What comes after sotorasib and adagrasib? Lung Cancer 107886 (2024).","DOI":"10.1016\/j.lungcan.2024.107886"},{"key":"2382_CR47","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard, D. et al. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 17, 984\u2013993 (2016).","journal-title":"Lancet Oncol."},{"key":"2382_CR48","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","volume":"18","author":"D Planchard","year":"2017","unstructured":"Planchard, D. et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 18, 1307\u20131316 (2017).","journal-title":"Lancet Oncol."},{"key":"2382_CR49","doi-asserted-by":"crossref","unstructured":"Subbiah, V. et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat. Med. 1\u201310 (2023).","DOI":"10.1038\/s41591-023-02321-8"},{"key":"2382_CR50","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jtho.2016.11.2218","volume":"12","author":"DR Gandara","year":"2017","unstructured":"Gandara, D. R. et al. A phase 1\/1b study evaluating trametinib plus docetaxel or pemetrexed in patients with advanced non\u2013small cell lung cancer. J. Thorac. Oncol. 12, 556\u2013566 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"2382_CR51","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/978-1-61779-080-5_34","volume":"731","author":"IV Bijnsdorp","year":"2011","unstructured":"Bijnsdorp, I. V., Giovannetti, E. & Peters, G. J. Analysis of drug interactions. Methods Mol. Biol. 731, 421\u2013434 (2011).","journal-title":"Methods Mol. Biol."},{"key":"2382_CR52","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"Chou T.-C.","year":"2006","unstructured":"Chou T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681 (2006).","journal-title":"Pharmacol. Rev."},{"key":"2382_CR53","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon, E. B. et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicenter, double-blind, randomized phase 3 trial. Lancet 384, 665\u2013673 (2014).","journal-title":"Lancet"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02382-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02382-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02382-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T23:02:38Z","timestamp":1757631758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02382-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2382"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02382-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experimental protocols were approved by the Ethics Committee of Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine. Written informed consent was obtained from all patients enrolled in this clinical study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"299"}}